Welcome to May's Scientific Newsletter
This month, we’re shining the spotlight on our IndEx-2 platform. ??
This powerful, inducible cell system allows selection of the safest and most efficacious targeted therapies. Our Director of Molecular Biology, Dr Tim London, explains:
“IndEx-2 is an in vitro cell-based platform that can determine the precise antigen density activation thresholds of candidate immunotherapies. This can help immuno-oncology drug developers build a better picture of their candidate therapeutic’s mechanism of action and safety profile.”
Currently, we’re the only service provider with IndEx-2 technology. Interested? Discover how we can help apply this platform to your antibody-targeted therapy.
Scientific Updates & Resources?
Effective IgG1 Fc silencing ???
A new innovation from mAbsolve demonstrates complete cessation of Fc binding and functional activities. This sets a new standard in the development of safer therapeutic antibodies. Read our research poster to find out more...
Upcoming Events & Conferences
Celebrating Discovery Week ??
领英推荐
27th-31st of May marks Antibody Analytics' Discovery Week! This is a chance for us to celebrate our achievements as a team and in the wider industry. Find out?what we’ve been up to this past year and keep an eye out for special social content.?
Antibody Analytics x SelectScience Webinar ??
Did you miss our latest webinar? Watch?our Senior Study Manager Dr Gavin Meehan present the different in vitro assays used for immuno-oncology drug discovery, as well as the new assays in development.
Conferences ??
Catch us stateside at these events:
Attending a conference? Pre-book a meeting with us.
Share your thoughts and leave us feedback! ??
How did you like our newsletter? What would you like to see in the future? Please email us your thoughts and suggestions to: [email protected].
Best wishes,
The Antibody Analytics Team.